Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: All three trials used similar regimens of azithromycin, and lung function improved after 3 to 6 months of treatment. The relative change in forced expiratory volume in 1 second predicted improved between 3.6% and 6.2%. Furthermore, the azithromycin treatment groups had improvement in a variety of secondary outcomes related to pulmonary exacerbations, including a reduction in antibiotic use (both intravenous and oral) and hospitalization rate. Furthermore, azithromycin was well tolerated: Only nausea, diarrhea, and wheezing (described as mild to moderate) occurred more frequently in the azithromycin group compared with the placebo group. The evidence for the clinical benefit of azithromycin in cystic fibrosis has been summarized in a Cochrane review in which a meta-analysis confirmed a significant improvement in forced expiratory volume in 1 second among the 286 pooled participants. SUMMARY:
|
Authors | Lisa Saiman |
Journal | Current opinion in pulmonary medicine
(Curr Opin Pulm Med)
Vol. 10
Issue 6
Pg. 515-23
(Nov 2004)
ISSN: 1070-5287 [Print] United States |
PMID | 15510060
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Azithromycin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Azithromycin
(therapeutic use)
- Cystic Fibrosis
(drug therapy, microbiology)
- Forced Expiratory Volume
(drug effects)
- Humans
- Pseudomonas Infections
(drug therapy)
- Pseudomonas aeruginosa
(drug effects)
- Randomized Controlled Trials as Topic
|